INDV
Indivior Pharmaceuticals, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
- Bridgewater AssociatesQ2 2026 · 37,141 shares+$1.22M
- Citadel AdvisorsQ2 2026 · 3,574,044 shares+$117.57M
- Two Sigma InvestmentsQ2 2026 · 175,767 shares+$5.78M
- D.E. ShawQ2 2026 · 203,985 shares+$6.71M
- AQR Capital ManagementQ2 2026 · 304,202 shares+$10.01M
- Millennium ManagementQ2 2026 · 4,595,535 shares+$151.17M
- Point72 Asset ManagementQ2 2026 · 94,943 shares+$3.12M
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $33 | — |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $33 | — |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $33 | — |
| D.E. Shaw re-entered | Q1 2025(8Q snapshot) | 5Q | $0.00 | $33 | — |
| Point72 Asset Management re-entered | Q2 2025(8Q snapshot) | 4Q | $0.00 | $33 | — |
| AQR Capital Management re-entered | Q4 2025(8Q snapshot) | 2Q | $0.00 | $33 | — |
| Bridgewater Associates | Q2 2026 | 1Q | $37 | $33 | -11% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Soros Fund Management | Q4 2025 | Q2 2026 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Indivior Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 10, 2026 — the most recent Form 4 on file — not from today.
- Form 40002014866-26-000011Jun 10, 2026
- Form 40001715258-26-000007May 14, 2026
- Form 40002014900-26-000009May 14, 2026
- Form 40001369067-26-000009May 14, 2026
- Form 40001257599-26-000008May 14, 2026
- Form 40001827169-26-000013May 14, 2026
- Form 40001487937-26-000009May 14, 2026
- Form 40001789507-26-000008May 14, 2026
- Form 40002014866-26-000008Mar 17, 2026
- Form 40001827169-26-000010Mar 13, 2026
- Form 40001369067-26-000006Mar 11, 2026
- Form 40001827169-26-000008Mar 11, 2026
- Form 40002014440-26-000007Mar 5, 2026
- Form 40002014866-26-000006Mar 5, 2026
- Form 40001484322-26-000013Mar 5, 2026
Fundamentals
XBRL · Indivior Pharmaceuticals, Inc.Annual figures sourced directly from Indivior Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Indivior Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 15, 2026
- 8-KMaterial eventMay 4, 2026
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementMar 27, 2026
- 8-KMaterial eventMar 17, 2026
- 8-KMaterial eventMar 13, 2026
- 8-KMaterial eventMar 12, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventJan 26, 2026
- 8-KMaterial eventJan 8, 2026
- 8-KMaterial eventDec 22, 2025
- 8-KMaterial eventDec 18, 2025
- 8-KMaterial eventDec 15, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q2 2026 | open | $37 | $33 | -11% |
| Citadel Advisors | Q2 2026 | open | $37 | $37 | -1% |
| Two Sigma Investments | Q2 2026 | open | $37 | $37 | -1% |
| D.E. Shaw | Q2 2026 | open | $37 | $37 | -1% |
| AQR Capital Management | Q2 2026 | open | $37 | $37 | -1% |
| Millennium Management | Q2 2026 | open | $37 | $37 | -1% |
| Point72 Asset Management | Q2 2026 | open | $37 | $37 | -1% |
| Soros Fund Management | Q4 2025 | Q2 2026 | $0.00 | — | +0% |
| AQR Capital Management | Q4 2025 | Q2 2026 | $0.00 | — | +0% |
| Point72 Asset Management | Q2 2025 | Q2 2026 | $0.00 | — | +0% |
| D.E. Shaw | Q1 2025 | Q2 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.